1. Scrip
  2. >>Archive

Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market

 
• By Emily Hayes

Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.

car racing in tunnel

Pfizer Inc./Merck KGAA are working fast to move their combination of the PD-L1 inhibitor Bavencio (avelumab) and Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) into the first-line advanced kidney cancer market, based on interim Phase III progression-free survival data.

The companies announced positive top-line results Sept. 11 for the combination of Bavencio with Pfizer's Inlyta vs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).